Cancer is fierce,
and so is our desire to beat it.
Meet the team that's taking on cancer.
We’re bringing together medical physics, nuclear medicine and radiotherapy in new ways to shift the paradigm of cancer care. Our belief in the difference we can make knows no bounds.
Invention of BgRT
When co-founder Akshay Nanduri visited long-time friend, Sam Mazin at Stanford University, they discussed the possibility of using cancer’s own biology to see and treat multiple tumors at the same time – an idea that would soon become a reality.
RefleXion is born
Just a short time after discussing the idea, Sam Mazin and Akshay Nanduri officially formed RefleXion Medical, a privately-held biotargeting oncology company headquartered in Hayward, CA.
First peer-reviewed publication
RefleXion publishes first paper in Medical Physics, the official journal of the American Association of Physicists in Medicine, that describes the RefleXion machine concept and the original BgRT approach for simulated lung and prostate cancers. It established the foundation for RefleXion’s clinical development program.
Funding the dream
RefleXion Medical successfully raised $11.6 million in Series A financing led by Paris-based Sofinnova Partners and joined by Pfizer Venture Investments (PVI), and Venrock.
RefleXion X1 Available for Sale
The RefleXion X1 receives clearance for SRS, SBRT and IMRT. This represents an important milestone for RefleXion on the journey to BgRT.
RefleXion raises $100 million in equity capital following the FDA clearance for the RefleXion X1. Led by PSP, one of Canada’s largest pension fund investors, this financing round positions RefleXion for commercial growth.
Just the Beginning
First Commercial Sale
RefleXion announces the first X1 sale for cancer treatment at a world renowned cancer center located in Northern California.
Stanford Treats First Patient
Physicians at Stanford Cancer Center treated the first patient using the RefleXion X1 for image-guided radiotherapy.
REFLEXION RECEIVES BREAKTHROUGH DEVICE DESIGNATION
The U.S. Food and Drug Administration (FDA) granted RefleXion Breakthrough Device Designation for its biology-guided radiotherapy* (BgRT) for use in treating lung tumors.
NEW SCIENTIFIC ADVISORY BOARD
RefleXion forms a multidisciplinary scientific advisory board, comprising 10 medical experts from radiation oncology, medical oncology and nuclear medicine.
RefleXion Wins 2022 Pantheon Award
RefleXion is awarded the 2022 Pantheon Award for Convergent Technologies from the California Life Sciences (CLS) organization – the state’s largest and most influential life sciences organization.
A NAME IS BORN
INTRODUCING THE SCINTIX THERAPY NAME
RefleXion introduces the SCINTIX therapy name for our flagship BgRT technology at the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting.
REFLEXION HOLDS CANCER SYMPOSIUM
RefleXion hosts top-tier clinicians from across the country at its first-ever cancer symposium at the newly dedicated Sanjiv “Sam” Gambhir Memorial Learning Center.
SCINTIX THERAPY IS FDA CLEARED
On February 2, 2023, RefleXion receives FDA clearance for SCINTIX biology-guided to treat patients with tumors in the lung or bone. For the first time ever, the cancer itself now aids in its own destruction.
Significant innovation in localized cancer treatment
With a bold mission and the drive to build a high-performing business, RefleXion captured the interest of blue-chip investors, all committed to advancing a new modality in cancer care, especially for stage-four cancer patients.
To date, RefleXion has raised nearly $400M from premier investment firms including TPG’s The Rise Fund, KCK Group, PSP Investments, Sofinnova, Ascension Ventures, T. Rowe Price, Ally Bridge Partners, Catalio Capital Management, Exor, Sixty Degree Capital, Venrock, Hillenbrand Capital Partners, global pharmaceutical leaders, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc. and Oxford Finance.
The National Cancer Institute (NCI) also provided grant funding through its Small Business Innovation Research (SBIR) Program.
Let us tell you more.Contact Us
Sign up for our
latest news and information.
Stay up to date.Sign Up